Subcommittee on Emerging Gene and Cell Therapies
Rodrigo T. Calado, MD, PhD ('21)
Katy Rezvani ('21)
Vahid Afshar-Kharghan, MD ('22)
Robert A. Brodsky, MD ('22)
Roland W. Herzog, PhD ('22)
Jennifer Holter-Chakrabarty, MD ('21)
Saad Sirop Kenderian, MD ('23)
Frederick Locke, MD ('23)
Sarah Nikiforow, MD, PhD ('23)
Sophie Paczesny, MD,PhD ('21)
Marcelo C. Pasquini, MD,MS ('21)
Steven Z. Pavletic, MD ('21)
Miguel-Angel Perales, MD ('21)
Fabiana Perna, MD ('23)
Matthew Porteus, MD, PhD ('23)
Paula Rio, PhD ('23)
Antonio M. Risitano, MD,PhD ('22)
Bipin N. Savani, MD ('22)
Nirali N. Shah, MD ('23)
Melody Smith, MD ('23)
Alice Kuaban, MS
Improving immune-based therapies for hematologic diseases is one of ASH’s research priorities. As the body of evidence continues to grow on the potential applications of these therapies, next-generation research must focus on the possible curative effects while also addressing the multiple challenges that still need to be overcome to ensure their optimal use.
The Subcommittee on Emerging Gene and Cell Therapies (under the purview of the Committee on Scientific Affairs) identifies barriers in the application of immune-based therapies to both malignant and non-malignant hematologic diseases, determines ways ASH could play a role in overcoming such barriers, and if appropriate, makes recommendations to the Society. Specifically, the subcommittee aims to develop useful resources for the hematology community aimed at:
· Understanding the state of the science as it relates to gene and cell therapies for the treatment of hematologic diseases.
· Advancing the use of immunotherapies for the treatment of non-malignant hematologic disease (e.g., complement targeting, immunotherapies for coagulation disorders, etc.).
· Educating investigators about CRISPR gene editing and its interplay with gene and cell therapies
· Providing physicians with information on how cellular therapies should be managed.
· Advocating for improved patient access to these therapies.
Members of the Subcommittee on Emerging Gene and Cell Therapies are appointed to three-year staggered terms (with the possibility of renewal for another three years) and include gene editing, gene therapy, as well as immunotherapy experts focused on both malignant and non-malignant hematology.
The chair and vice chair each serve one-year terms with the immediate past chair serving another one-year term on the subcommittee as a member. If not already a member of the Committee on Scientific Affairs, the Chair of the Subcommittee on Emerging Gene and Cell Therapies serves as a liaison to the Committee on Scientific Affairs. The subcommittee’s leadership always represents both malignant and non-malignant hematology.
Members of the Subcommittee on Emerging Gene and Cell Therapies are required to participate in regularly scheduled conference calls and possibly one in-person meeting if deemed necessary.